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ABSTRACT
Objective: Systemic sclerosis (SSc) is a generalised
autoimmune disease, causing morbidity and a reduced life
expectancy, especially in patients with rapidly progressive
diffuse cutaneous SSc. As no proven treatment exists,
autologous haematopoietic stem cell transplantation
(HSCT) is employed as a new therapeutic strategy in
patients with a poor prognosis. This study reports the
effects on survival, skin and major organ function of HSCT
in patients with severe diffuse cutaneous SSc.
Patients and methods: A total of 26 patients were
evaluated. Peripheral blood stem cells were collected
using cyclophosphamide (4 g/m2) and rHu G-CSF (5 to
10 mg/kg/day) and were reinfused after positive CD34+
selection. For conditioning, cyclophosphamide 200 mg/kg
was used.
Results: After a median follow-up of 5.3 (1–7.5) years,
81% (n = 21/26) of the patients demonstrated a clinically
beneficial response. The Kaplan–Meier estimated survival
at 5 years was 96.2% (95% CI 89–100%) and at 7 years
84.8% (95% CI 70.2–100%) and event-free survival,
defined as survival without mortality, relapse or progres-
sion of SSc, resulting in major organ dysfunction was
64.3% (95% CI 47.9–86%) at 5 years and 57.1% (95% CI
39.3–83%) at 7 years.
Conclusion: This study confirms that autologous HSCT in
selected patients with severe diffuse cutaneous SSc
results in sustained improvement of skin thickening and
stabilisation of organ function up to 7 years after
transplantation.
Systemic sclerosis (SSc) is a generalised connective
tissue disorder characterised by vascular lesions,
resulting in thickening of the skin, fibrotic degen-
erative changes in muscles, joints and viscera, mainly
the intestinal tract, the heart, the lungs and the
kidneys.1 2 Although its exact pathogenesis remains
unknown, this autoimmune disease is characterised
by predominant T-cell activation, the production of
specific auto antibodies, and cytokine release.3 4 Two
main clinical subsets, namely limited and diffuse
cutaneous forms, can be distinguished by the extent
of skin involvement, their autoantibody profile and
the pattern of organ involvement. The mortality of
SSc is high, with a 5-year mortality rate of at least
30%.5 6 In rapidly progressive diffuse cutaneous SSc
the 5-year mortality is estimated to be 40–50%.5–9 In
these patients, the cause of death is secondary to
pulmonary, cardiac and renal involvement.5 6 10 To
date, no treatment has been shown to prevent
disease progression and reverse fibrosis, but immu-
nosuppressive therapy, given at an early stage of the
disease, could result in disease improvement.
Reduction of the skin score and stabilisation or
improved global response was suggested by one
small placebo controlled study with methotrexate.11
This was later confirmed in a second, larger placebo-
controlled randomised study.12 More recently, a
large, double-blind placebo controlled trial with oral
cyclophosphamide in SSc patients with interstitial
lung disease showed a statistically significant,
although clinically modest, effect, namely a reduc-
tion of decline of forced vital capacity (FVC).13 A
similar study with monthly intravenous bolus of
cyclophosphamide and prednisolone 20 mg every
other day for 6 months, followed by oral azathiopr-
ine (2.5 mg/kg/day) for 6 months showed positive
effects on the FVC, but not on carbon dioxide
diffusion lung capacity (DLCO) or abnormalities on
high-resolution CT-scan.14
Since 1996, autologous peripheral blood stem cell
(PBSC) transplantation has been employed world-
wide with a low early mortality of ,5%.15–18 Based
on these data, we have used intensive myelo- and
immunosuppression followed by autologous haema-
topoietic stem cell transplantation (HSCT) to treat
severe SSc.15 17 19 Since 1996, approximately 1000
PBSC transplantations for autoimmune diseases
have been reported20 21 with 140 SSc patients in the
EBMT (European Group for Blood and Marrow
Transplantation) and EULAR (European League
Against Rheumatism) database as to March 2007.
The early results from the phase I/II clinical trials
showed that HSCT is feasible in carefully selected
patients with diffuse SSc.16 19 22 23 In 2004, a follow-
up report from the EBMT-EULAR database, con-
sisting of different centres and treatment schemes,
showed positive responses at 3 years in two thirds of
57 patients with an early treatment related mortal-
ity of 8.7%.15 We describe here the long-term follow-
up results of all the Dutch and French patients
included in two similar phase I/II trials, using
uniform eligibility criteria and a single transplanta-
tion protocol.24 The specific aims of this study were
to evaluate the survival and the durability of
responses up to 7 years of follow-up in SSc patients
treated by autologous HSCT.
PATIENTS AND METHODS
We report results from patients with SSc, treated
by HSCT at the Radboud University Nijmegen
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Medical Centre and the Leiden University Medical Centre in
The Netherlands and at the Hoˆpital Saint-Louis in Paris, France,
with at least 6 months follow-up after HSCT. All patients
fulfilled the ACR preliminary criteria for SSc and had the diffuse
cutaneous form.3 Patients were eligible if they had the following
characteristics: (a) age ,66 years and (b) rapidly progressive
disease (2 years duration with a modified Rodnan skin score
(mRSS) above 20, plus ESR .25 mm/first h and/or Hb ,11 g/
dL, not explained by other causes than active SSc or (c) a disease
duration .2 years plus a progression of the mRSS (.20%) plus
major organ involvement related to SSc as defined by either: (1)
lung involvement: with a vital capacity (VC) or DLCO below
70% predicted, or a mean pulmonary artery pressure (PAP)
above 40 mmHg (measured by echocardiography); (2) digestive
tract involvement: with serum albumin ,25 g/L or weight loss
exceeding 10% body weight in the preceding year; (3) kidney
involvement: with 24-h urinary protein above 0.5 g or serum
creatinine above 120 mmol/L. The exclusion criteria were:
uncontrolled arrhythmia, echocardiographic left ventricular
ejection fraction (LVEF) ,50% or mean PAP .50 mmHg,
DLCO ,45% of predicted, creatinine clearance ,20 ml/min,
platelets ,80 000/mm3, haemorrhagic cystitis, HIV or HTLV1
seropositivity, malignancy, pregnancy, a cardiac or vascular
prosthesis, and no vascular access.19 These studies were approved
by the local ethics committees.19 After obtaining written informed
consent, eligible patients were included in the protocol.
Pre-treatment evaluation
Pre-transplant evaluation included: (1) disease characteristics
such as the disease duration (in years from the first non-
Raynaud symptom), autoantibody profile, previous disease
specific treatment and determination of WHO performance
status, grade 0–5; grade 0 being a patient who is fully active
without restriction; grade 1 being a patient who is restricted in
physically strenuous activity, but ambulatory and able to carry
out work; grade 2 representing a patient who is ambulatory and
capable of all self-care but unable to carry out any work, up and
about.50% of the waking hours; grade 3 being a patient who is
capable of only limited self-care, confined to bed or chair .50%
of waking hours; grade 4 representing a patient who is
completely disabled and cannot carry out any self-care, who is
totally confined to bed and chair; and grade 5 a deceased
patient;25 (2) organ involvement according to: (a) the extent of
skin sclerosis using the mRSS;10 (b) chest x ray or high-
resolution CT-scan, pulmonary function tests with total lung
capacity (TLC), VC, forced expiratory volume in first second
(FEV1), and DLCO, all in % of predicted; (c) echocardiography
to measure LVEF (%) and mean PAP (mmHg); (d) estimation of
the creatinine clearance according to the method of Cockcroft
and Gault.26
Stem cell mobilisation, collection and selection: transplantation
procedure
The transplantation procedure was performed as previously
reported.19 In short, the mobilisation and collection of PBSC was
performed with 4 g/m2 cyclophosphamide followed 4–5 days
later by rHu G-CSF (LenograstimH, Aventis and Chugai Pharma
France or FilgrastimH, Amgen, Thousand Oaks, California,
USA) 5 or 10 mg/kg/day until the last apheresis. Autologous
PBSC were collected when CD34+ cells were above 20/ml in
peripheral blood. At least 9.56106 CD34+/kg had to be collected
by successive daily apheresis to obtain 76106 CD34+/kg for
positive selection (using Nexel IsolexH300i Stem Cell Collection
System at St Louis Hospital and ClinimacsH of Miltenyi in
Nijmegen and Leiden) and 2.56106 CD34+/kg for haematopoie-
tic rescue.27 The graft was 4–5 log T-cell depleted. Conditioning
was performed at least 4 weeks later using cyclophosphamide at
50/mg/kg/day from day –5 to day –2 prior to PBSC reinjection.
Clinical follow-up
To assess the survival and disease response to treatment, clinical
evaluation was conducted at least every 6 months, consisting of
the same investigations that were used in the pre-transplanta-
tion evaluation. Event-free survival (EFS) was defined as
survival without mortality, relapse or progression of SSc,
resulting in heart, lung or kidney dysfunction. Organ dysfunc-
tion was defined as follows: heart: an echocardiographic
LVEF,40% or mean PAP .50 mmHg; pulmonary: respiratory
failure with a paO2 ,8 kPa/60 mmHg; kidney failure necessi-
tating dialysis. Response to therapy was assessed segregating
major (MR) or partial (PR) responses, no response, disease
progression or relapse as previously described.19 A major
response was defined as: (1) performance status at 0; plus (2)
decrease .50% in the mRSS and/or an increase in FEV1 .30%,
plus an LVEF .45% without any pericardial effusion and serum
creatinine ( baseline values. A partial response was defined as:
(1) performance status (1; plus (2) decrease 25%–50% in mRSS
and/or an increase in FEV1 15%–30%, plus an LVEF .45% with
no or small pericardial effusion plus serum creatinine at baseline
values or ,180 mmol/L. No response was defined by stable
disease compared to inclusion. Relapse was defined by the onset
of progression after prior response. Disease progression was
defined as an increase in mRSS .25% compared to the baseline
values, a decrease in VC or DLCO .15% and/or major organ
dysfunction as defined above.
Statistical analysis
Categorical variables were summarised as counts and percen-
tage, while numerical variables were summarised as median and
full range. Outcomes were reported for each follow-up year.
Groups were compared using Fisher’s exact test for the
categorical variables and non-parametric paired Wilcoxon rank
sum test for numerical variables. The significance level of
p values was set to 0.05. The survival curve was calculated by
the Kaplan–Meier method. A piecewise linear mixed model was
used to represent the mRSS over follow-up, with the first linear
part from inclusion to the first year of follow-up, and the second
part from the first up to the seventh year of follow-up.28
Random subject main effect and slope were added to the
model, to account for the correlation between measurements on
the same subjects. All computation analyses were performed
using R (http://cran.r.project.org) version 2.1 for Windows.
RESULTS
Patients
A total of 26 patients (19 females and 7 males), median age 42
(16–65) years, with diffuse cutaneous SSc were included in the
study (11 from Nijmegen, 10 from Paris and 5 from Leiden)
from March 1998 to May 2004. Table 1 shows baseline patients’
clinical characteristics. Two patients included were subse-
quently found as having one of the exclusion criteria (one with
a DLCO at 21% and one with a LVEF of 46%), which were
considered as violation of the protocol but could be kept in the
study according to the study committee advice. A total of 12
patients had early diffuse SSc, with a median disease duration of
1.4 (0.8–2) year, and 14 patients had progressive organ
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involvement with a median disease duration 3.7 (2.1–13) year.
The median mRSS of 32 (9–51) and 85% (n = 22) had an mRSS
>20. Pulmonary involvement was present in 65% (n = 17), and
19% (n = 5) had a creatinine clearance below 70 ml/min.
Significant weight loss was one of the eligibility criteria in
19% of the cases (n = 5). All but three patients had been treated
with immunosuppressive agents prior to the HSCT (metho-
trexate, prednisolone, cyclophosphamide with a maximum of 9
gram per patient, d-penicillamine, colchicine, azathioprine,
sulphasalasine, interferon a, infliximab, and anti-TGF b).
These agents were discontinued at least 1 month prior to
PBSC mobilisation. In five patients relevant co-morbidity, such
as diabetes mellitus (n = 1), asthma (n = 2) and ischaemic heart
disease (n = 2) was present.
The treatment regimen is described in table 2. In one patient,
PBSC mobilisation failed, but enough bone marrow stem cells
were harvested 4 weeks later and autologous bone marrow
transplantation was performed with antilymphocytes globulins
and cyclophosphamide.15 Another patient received PBSC trans-
plantation without T cell depletion due to technical problems at
the time of the selection procedure.
Survival
The early mortality, within 6 months after HSCT, was
previously reported for all patients.15 19 In short, among 28
severe SSc patients treated by HSCT 2 died within 6 months
(7.1%), leaving 26 patients with at least 6 months of follow-up
after HSCT. The causes of death of these two patients was
considered as treatment related at 1 month for one patient and
due to disease progression for another at 6 months after HSCT.
As illustrated in fig 1, the probability of survival of SSc patients
with at least 6 months follow-up after HSCT was 96.2% (95%
CI 89–100%) at 5 years and 84.8% (95% CI 70.2–100%) at 7
years. At the time of analysis, no patients were lost to follow-
up. After a median follow-up of 5.2 (1–7.5) years, death from
disease progression occurred in 2 patients (8%): both from
relapse at 18 months after transplantation, one after initial PR
and the other after initial MR. A third patient, a heavy smoker,
died from small cell lung cancer 64 months after HSCT. Among
the others showed 35% (n = 9) sustained MR, 50% (n = 13)
sustained PR, and 3% (n = 1) progressed after PR. All together,
the event-free survival (EFS) for the patients with at least
6 months of follow-up after autologous HSCT was 64.3% (95%
CI 47.9–86.3%) at 5 years and 57.1% (95% CI 39.3–83.1%) at 7
years (fig 1).
Long-term morbidity
Infectious complications occurred in 19% (n = 5) of the
patients, caused by Herpes Zoster reactivation (n = 3) and
atypical mycobacterium (n = 2). One patient with persistent
pancytopenia after HSCT received 16 units of red blood cells
and recovered suboptimal blood counts after discontinuing
simultaneous treatment with co-trimoxazole. One patient
developed a basal carcinoma of the facial skin at 4 years after
transplantation, which was surgically removed.
Clinical evolution
The WHO performance status improved throughout the follow-
up, from baseline values at median 2.12 (0–4, n = 26) to 0.60 (0–
2, n = 15 p,0.05) after 5 years of follow-up (fig 2).
A significant fall in mRSS was observed up to 7 years after
HSCT with faster regression within the first year and sustained
fall thereafter. The representation of the mRSS by a linear
mixed model resulted in a median mRSS decrease of 11.57 units
in the first year (p,0.001) and of 2.57 units per year after that
(p,0.001) (tables 3 and 4 and fig 3). A significant decrease
Table 1 Baseline clinical characteristics in severe systemic sclerosis
(SSc) patients treated by autologous haematopoietic stem cell
transplantation with at least 6 months follow-up after the procedure
n = 26
Age (years), median (range) 42 (16–65)
Sex (F/M) 19/7
Disease duration (years), median (range) 2.0 (0.8–13)
Skin involvement:
Modified Rodnan skin score .50% maximum 19 (73%)
Modified Rodnan skin score, median (range) 32 (9–51)
Lung involvement:
TLC ,70% of predicted value 8 (31%)
VC ,70% of predicted value 9 (35%)
DLCO ,70% of predicted value 17 (65%)
Cardiovascular involvement:
Arterial hypertension 1 (4%)
LVEF .40% 26 (100%)
Pericardial effusion present 2 (8%)
Kidney involvement:
Creatinine clearance .100 ml/min 12 (46%)
Creatinine clearance .70 and ,100 ml/min 11 (42%)
Creatinine clearance ,70 ml/min 3 (12%)
Digestive tract involvement:
Weight loss .10% in last 6 months 7 (27%)
Diarrhoea .4 times/day 3 (12%)
Parenteral nutrition 2 (8%)
WHO performance status:
Grade 0 1 (4%)
Grade I 9 (35%)
Grade II 9 (35%)
Grade III 5 (12%)
Grade IV 2 (8%)
Serum auto antibodies:
ANA positive 25 (96%)
Anticentromere positive 1 (4%)
Antitopoisomerase positive 12 (46%)
DLCO, carbon dioxide diffusion lung capacity; LVEF, left ventricular ejection fraction;
TLC, total lung capacity; VC, vital capacity; WHO, World Health Organization.
Table 2 Regimen used in severe systemic sclerosis (SSc) patients
treated by autologous haematopoietic stem cell transplantation with at
least 6 months follow-up after the procedure
Number of patients
(%) total n = 26
Mobilisation procedure:
CMP 2 g/m2/d, two successive days + G-CSF 10 (39%)
CMP 4 g/m2/d, one day + G-CSF 16 (62%)
Number of apheresis/patient 1.2 (0–2)
No mobilisation and no selection 1 (4%)
No CD34+ selection 1 (4%)
CD34+ selection 24 (92%)
CD34+ 106/kg 6.7 (2.4–17.4)
Conditioning regimen:
CMP alone (200 mg/kg 64) 25 (96%)
ALG + CMP (200 mg/kg 64) 1 (4%)
Autologous transplantation 26
CD34+ PBSC 24 (92%)
Non-selected PBSC 1 (4%)
Bone marrow stem cells 1 (4%)
ALG, anti-lymphocyte globulins; CMP, cyclophosphamide; PBSC, peripheral blood
stem cell.
Extended report
100 Ann Rheum Dis 2008;67:98–104. doi:10.1136/ard.2007.071464
(.25%) in mRSS was achieved in 73% (n = 19/26) of the
patients after 1 year and in 94% (15/16) after 5 years.
Repeated assessments of pulmonary function parameters
were obtained in all patients every 6 months with 15 patients
completing 5 years of follow-up. The median VC (% predicted)
was 76% (37–143%) at inclusion and 73% (33–114%) after 5
years of follow-up. In comparison with baseline values for all
patients, there was no significant change in FEV1 or DLCO
during follow-up. Cardiac and renal function remained stable
during follow-up (tables 3 and 4).
After autologous HSCT 81% (n = 21/26) of the patients with
at least 6 months follow-up demonstrated a positive response at
one year with either major (n = 5) or partial (n = 16) response,
whereas 5 patients had no response (fig 4).19 Longer follow-up
showed that after 5 years 82% (n = 14/17) had a response to the
transplantation.
Relapses occurred in 28% (n = 6) of the initial major (n = 2) or
partial (n = 4) responders within 2.7 (range 2–4) years after
transplantation. Treatment of the relapses consisted of either
corticosteroids (n = 3), corticosteroids plus mycophenolate-
mophetil (n = 1), or corticosteroids plus mycophenolate-mophe-
til plus cyclosporine A (n = 2). After a median follow-up of 5.3
(1–7.5) years, 88% (n = 23/26) of the patients with at least
6 months follow-up after HSCT were alive: 35% (n = 9) with
MR, 50% (n = 13) with PR, and 3% (n = 1) with progression
after PR.
DISCUSSION
The data presented here were obtained from the combined
Dutch–French database of patients with SSc treated by HSCT
in a phase I/II study. The primary objectives of this study were
to assess the long-term survival. The secondary objectives were
to evaluate the disease response after HSCT, using previously
published criteria,19 to assess the evolution of the functional
status, the skin involvement as well as organ involvement.
The cohort of patients studied represented a group with SSc
and poor prognosis, as assessed by their initial high mRSS, the
number of patients with lung disease and the presence of anti-
topoisomerase auto antibodies.6–9 29–39 The treatment regimen, as
well as clinical follow-up after transplantation employed in the
three hospitals were similar. To our knowledge, this is the
largest cohort of severe SSc patients studied, with a median
follow-up period of 5.3 years after autologous HSCT, providing
valuable information on long-term outcome.
Benefits and mortality
This study illustrates the benefits that can be observed after
HSCT in severe SSc patients. The adequate selection of patients
with a poor prognosis, but without irreversible organ damage, is
important to reduce the treatment risks and to improve the
treatment success.22 29 After a median follow-up of 5.3 (1–7.5)
years, death from disease progression occurred in 8% of our SSc
patients. This rate is strikingly lower compared to the 5-year
mortality rate estimated at 40% in such severe SSc patients,
according to a recently published meta-analysis.6 The positive
effect of HSCT on survival rate needs to be interpreted with
care, due to a wide range in the duration of patients’ follow-up
and the uncontrolled nature of this study, but the results are
encouraging.
Autologous HSCT induced a rapid skin score decline. To our
knowledge, no other therapeutic intervention in diffuse SSc has
ever shown such a rapid and sustained improvement in skin
condition. In our cohort, a significant decrease in mRSS was
achieved in 73% after 1 year and in 94% (15/16) after 5 years.
The skin thickness in patients with early SSc may improve
spontaneously. However, the time span of such changes has
always appeared much slower than observed within the first
year after autologous HSCT.40 Further studies will help to
clarify the pathological mechanisms associated with regression
Figure 1 Kaplan–Meier survival curve
(A) and event-free survival (EFS) curve
(B) in 26 severe systemic sclerosis (SSc)
patients with at least 6 months follow-up
after autologous haematopoietic stem cell
transplantation and 95% confidence
intervals.
Figure 2 World Health organization (WHO) performance status among
the 26 severe systemic sclerosis (SSc) patients with at least six months
follow-up after treatment by autologous haematopoietic stem cell
transplantation.
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of skin sclerosis as recently shown after autologous HSCT in
SSc.41
Interstitial pulmonary disease accounts for a large part of
mortality in SSc patients. The effects of current treatment
protocols of interstitial pulmonary disease in SSc is not very
successful.13 In our study 65% of the patients with severe SSc
had significant lung involvement at inclusion. All pulmonary
function parameters remained stable after 5 and 7 years of
follow-up.
The strongest effect of treatment by HSCT was observed on
functional status, as assessed by the WHO performance status,
possibly due to improvement of the skin condition. Five years
after transplantation, the percentage of patients with a WHO
performance status of zero had increased to 56% compared to
4% at baseline. Therefore, HSCT treatment showed a sustained
positive effect on the combination of functional status, skin,
lung, heart and kidney involvement.19
Our study has several limitations. First, this uncontrolled
study and the promising results obtained in a relatively small
number of patients will have to be confirmed in larger numbers
as aimed in the two ongoing phase III randomised trials
comparing autologous HSCT to monthly cyclophosphamide
intravenously, the European ASTIS trial and the North
American SCOT study. Nonetheless, to our knowledge this is
the largest cohort of SSc patients studied after autologous
HSCT, providing a rather good estimation of the long-term
outcome and treatment effects at 5 years. Secondly, the natural
history of SSc in some patients may lead to a more indolent
disease after a period of active disease, resulting in stabilisation
of organ functions and reduction of the mRSS. However, no
study has yet found the predictive factors to distinguish such
patients. Furthermore, large cohorts of SSc patients prospec-
tively studied by Steen37 and Scuzel42 have shown the very
severe spontaneous evolution of SSc in some cases.
In conclusion, for the first time this extended report shows the
long-term follow-up results of HSCT in patients with severe SSc.
It is confirmed that this treatment is feasible with acceptable
toxicity.15 19 22–24 Clinical significant and sustained improvement
was found on the skin condition and functional status with
pulmonary cardiac and renal function stabilisation. Combined
results allowed us to show that the majority of the patients
experienced a sustained complete or partial remission of SSc.
Table 3 Clinical evolution in the 26 systemic sclerosis (SSc) patients treated by autologous haematopoietic stem cell transplantation with at least
6 months follow-up after the procedure
Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
mRSS
Median (range) 32 (9–51) 19 (3–51) 12 (0–49) 7 (3–43) 4 (0–35) 4 (0–34) 5 (0–19 3 (2–10)
n 26 26 20 18 16 15 6 3
DLCO
Median (range) 55 (21–100) 52 (26–100) 58 (21–100) 58 (15–94)* 50 (16–85){ 52 (17–75) 62 (11–74) 75 (18–76)
n 26 25 18 19 15 11 4 3
VC
Median (range) 76 (37–143) 84 (43–138) 84 (37–133) 96 (32–128)* 74 (30–114){ 73 (33–114) 79 (34–95) 81 (32–95)
n 26 26 19 19 16 11 4 3
FEV1
Median (range) 76 (44–116) 85 (37–128) 89 (40–129) 80 (38–120) 75 (40–114) 71 (39–114) 73 (38–83) 71 (37–143)
n 26 26 19 19 16 11 4 3
LVEF
Median (range) 63 (46–84) 64 (49–75) 62 (45–71) 60 (52–70) 60 (50–71) 67 (57–74) 63 (59–67) NA
n 22 18 16 10 8 9 2 0
Creatinine
clearance
Median (range) 92 (55–188) 92 (49–222) 92 (49–203) 90 (60–180) 84 (60–175) 92 (60–232) 98 (67–280) 92 (51–97)
n 26 25 21 19 17 15 6 3
*For the 19 patients evaluated at 3 years, VC was 77 (43–130) at inclusion and 96 (32–128) at 3 years, while FEV1 was 76 (48–116) at inclusion and 80 (38–120) at 3 years.
{For the 16 patients analysed at 4 years, VC was 74 (43–111) at inclusion and 73 (30–114) at 3 years, while FEV1 was 73 (48–112) at inclusion and 74 (40–114) at 4 years.
DLCO, carbon dioxide diffusion lung capacity; VC, vital capacity; FEV1, forced expiratory volume in first second; LVEF, left ventricular ejection fraction.
Table 4 Relative changes (median, range) from baseline for the 26 systemic sclerosis (SSc) patients treated
by autologous haematopoietic stem cell transplantation with at least 6 months follow-up after the procedure
Relative change from
baseline 1 year (n = 26) 3 year (n = 20) 5 year (n = 15)
mRSS 239% (286%; 59%) 272% (2100%; 33%) 273% (2100%; 225%)
p*,1023 p*,1023 p*,1023
VC 4% (213%; 77%) 3% (232%; 93%) 27% (238%; 89%)
p* = 0.019 p* = 0.044 p = 0.50
TLC 0 (231%; 32%) 1% (242%; 66%) 21% (245%; 62%)
p = 0.98 p = 0.65 p = 0.78
FEV1 6% (233%; 91%) 6% (228%; 100%) 23% (256%; 100%)
p*,0.047 p = 0.61 p = 0.42
DLCO 24% (243%; 53%) 27% (262%; 74%) 29% (259%; 64%)
p = 0.09 p = 0.31 p = 0.41
mRSS, modified Rodnan Skin Score; VC, vital capacity; TLC, total lung capacity; FEV1, forced expiratory volume in first second;
DLCO, carbon dioxide diffusion lung capacity. p*, paired Wilcoxon rank test p value.
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